Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor
Open Access
- 8 October 2004
- journal article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 12 (1), 26-34
- https://doi.org/10.1038/sj.cgt.7700754
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked LigandsJournal of Virology, 2002
- Adeno-Associated Virus Vector-Mediated Minidystrophin Gene Therapy Improves Dystrophic Muscle Contractile Function inmdxMiceHuman Gene Therapy, 2002
- Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapyGene Therapy, 2002
- Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1Gene Therapy, 2002
- An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene ExpressionMolecular Therapy, 2001
- Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal NeovascularizationHuman Gene Therapy, 2001
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophiliaGene Therapy, 1998
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996